# OnCo record lung-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/lung-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "lung-cancer" ;
  schema:name "Lung cancer (all types)"@en ;
  schema:alternateName "Bronchogenic carcinoma"@en, "Lung carcinoma"@en, "Cancer of the lung"@en, "Trachea, bronchus and lung cancer"@en, "Lung and bronchus cancer"@en, "Carcinoma of the lung"@en ;
  schema:description "Lung cancer splits into non-small-cell disease, about 85 percent of it, and small-cell disease, which was 6.6 percent of English cases in 2024 and 9.1 percent of Welsh ones (National Lung Cancer Audit, State of the Nation 2026); the two behave and are treated very differently. Screening, staging and the things both types share are common ground; the rest belongs to each subtype."@en ;
  schema:url <https://onco.cc/cancers/lung-cancer/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lung_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Lung_cancer>, <https://www.cancer.gov/types/lung>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/lungb.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors>, <https://www.nhs.uk/conditions/lung-cancer/>, <https://www.nhs.uk/conditions/lung-cancer/symptoms/>, <https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://www.nice.org.uk/guidance/ng122/chapter/Diagnosis-and-staging>, <https://www.nice.org.uk/guidance/ng209>, <https://view-health-screening-recommendations.service.gov.uk/lung-cancer/>, <https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner>, <https://doi.org/10.1056/nejmoa1102873>, <https://doi.org/10.1056/nejmoa1911793>, <https://doi.org/10.1001/jama.2021.1117>, <https://doi.org/10.1001/jama.2021.0377>, <https://doi.org/10.1038/s41591-026-04292-y>, <https://doi.org/10.1093/bjr/tqaf161>, <https://doi.org/10.1016/j.jtho.2024.02.011>, <https://doi.org/10.1016/j.jtho.2021.11.003>, <https://doi.org/10.1016/s2213-2600(24)00428-4>, <https://doi.org/10.1038/s44276-023-00006-w>, <https://www.nhs.uk/conditions/lung-cancer/tests-and-next-steps/>, <https://www.nhs.uk/conditions/lung-cancer/treatment/>, <https://www.nhs.uk/symptoms/coughing-up-blood/>, <https://www.nhs.uk/better-health/quit-smoking/>, <https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/>, <https://www.nhs.uk/tests-and-treatments/clinical-trials/>, <https://www.nice.org.uk/guidance/ng122/chapter/Management>, <https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care>, <https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists>, <https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives>, <https://www.nice.org.uk/guidance/ng234/chapter/Recommendations>, <https://roycastle.org/learn-about-lung-cancer/living-with-cancer/>, <https://roycastle.org/our-support/>, <https://roycastle.org/our-support/stop-smoking/>, <https://roycastle.org/learn-about-lung-cancer/getting-diagnosed/>, <https://roycastle.org/learn-about-lung-cancer/lung-cancer-treatments/>, <https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/non-small-cell-lung-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping>, <https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/treatment/help-you-breathe>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/metastatic/symptoms>, <https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/treatment/oxygen-at-home>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/resources-books>, <https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness>, <https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness/how-can-i-manage-my-breathlessness>, <https://www.maggies.org/support-and-information/>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://doi.org/10.1056/NEJMoa1000678> ;
  onco:tag "parent-page" ;
  onco:related <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/lung-lcnec/>, <https://onco.cc/cancers/lung-net/>, <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/pleuropulmonary-blastoma/>, <https://onco.cc/cancers/lung-adenocarcinoma/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/>, <https://onco.cc/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/>, <https://onco.cc/ideas/idea-lung-never-smoker-disease-its-own-programme/>, <https://onco.cc/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/>, <https://onco.cc/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/>, <https://onco.cc/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/>, <https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/>, <https://onco.cc/ideas/idea-lung-uk-screening-testing-and-access-gaps/> ;
  onco:technologies <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/nhs-targeted-lung-health-check/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/eras-perioperative-nutrition/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/terms/stereotactic-radiosurgery/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/lurbinectedin/> ;
  onco:terms <https://onco.cc/terms/targeted-lung-health-check/>, <https://onco.cc/terms/pack-year/>, <https://onco.cc/terms/never-smoker-lung-cancer/>, <https://onco.cc/terms/tnm-9-lung-cancer/>, <https://onco.cc/terms/radon/>, <https://onco.cc/terms/asbestos/>, <https://onco.cc/terms/smoking-cessation/>, <https://onco.cc/terms/haemoptysis/>, <https://onco.cc/terms/pulmonary-nodule/>, <https://onco.cc/terms/lung-rads/>, <https://onco.cc/terms/pancoast-tumour/>, <https://onco.cc/terms/ttf1-p40/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/malignant-pleural-effusion/>, <https://onco.cc/terms/superior-vena-cava-obstruction/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/terms/pneumonectomy/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/immune-colitis/>, <https://onco.cc/terms/pleural-effusion/>, <https://onco.cc/terms/pleurodesis/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/histology/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/terms/overdiagnosis/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/screening/>, <https://onco.cc/terms/lung-trials-open-today/>, <https://onco.cc/terms/lung-palliation-breathlessness-effusion-obstruction/>, <https://onco.cc/terms/lung-failed-programmes/>, <https://onco.cc/terms/lung-uk-drug-access/> ;
  onco:trials <https://onco.cc/trials/nlst-nelson/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/laura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/trials/alex/>, <https://onco.cc/trials/crown/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/trials/lung-map/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-prevention-adoption/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-brain-delivery/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-trial-diversity/> ;
  onco:pipeline <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/>, <https://onco.cc/ideas/idea-lung-never-smoker-disease-its-own-programme/>, <https://onco.cc/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/>, <https://onco.cc/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/>, <https://onco.cc/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/>, <https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/>, <https://onco.cc/ideas/idea-lung-uk-screening-testing-and-access-gaps/> ;
  onco:standardOfCare <https://onco.cc/terms/haemoptysis/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/smoking-cessation/>, <https://onco.cc/terms/radon/>, <https://onco.cc/terms/asbestos/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/terms/pneumonectomy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/laura/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/ret/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/keynote-407/>, <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/terms/irae/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/trials/laura/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/terms/pleurodesis/>, <https://onco.cc/terms/pleural-effusion/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/trials/nlst-nelson/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/trials/nhs-galleri/>, <https://onco.cc/trials/jcog0802/>, <https://onco.cc/trials/calgb-140503/>, <https://onco.cc/trials/lace-pooled-analysis/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/terms/minimally-invasive-surgery/>, <https://onco.cc/trials/chisel/>, <https://onco.cc/trials/stars-rosel/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/trials/ialt/>, <https://onco.cc/trials/jbr-10/>, <https://onco.cc/trials/anita/>, <https://onco.cc/trials/lace-pooled-analysis/>, <https://onco.cc/trials/lung-art/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/lung-uk-drug-access/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/trials/neotorch/>, <https://onco.cc/trials/nct04379635/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/keynote-091/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/terms/efs/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/pacific-2/>, <https://onco.cc/trials/laura/>, <https://onco.cc/trials/rtog-0617/>, <https://onco.cc/trials/gemstone-301/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/consolidation-therapy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/tps/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/trials/impower110/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/flaura/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/aura3/>, <https://onco.cc/trials/nct01774721/>, <https://onco.cc/trials/lux-lung-3/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/trials/nct04538664/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/mobocertinib/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/trials/lux-lung-3/>, <https://onco.cc/trials/crown/>, <https://onco.cc/trials/alex/>, <https://onco.cc/trials/alesia/>, <https://onco.cc/trials/j-alex/>, <https://onco.cc/trials/alta-1l/>, <https://onco.cc/trials/profile-1014/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/trials/nct03093116/>, <https://onco.cc/trials/profile-1001-ros1/>, <https://onco.cc/trials/nct02568267/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/taletrectinib/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/codebreak-100/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/trials/nct02864992/>, <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/terms/met-exon-14-skipping/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/libretto-431/>, <https://onco.cc/trials/nct03157128/>, <https://onco.cc/trials/arrow-thyroid/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/trials/brf113928/>, <https://onco.cc/trials/pharos/>, <https://onco.cc/trials/destiny-lung02/>, <https://onco.cc/trials/destiny-lung01/>, <https://onco.cc/trials/nct02912949/>, <https://onco.cc/trials/navigate/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/impower110/>, <https://onco.cc/trials/empower-lung-1/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/checkmate-026/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-407/>, <https://onco.cc/trials/squire/>, <https://onco.cc/trials/impower150/>, <https://onco.cc/trials/nct03164616/>, <https://onco.cc/trials/checkmate-9la/>, <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/trials/checkmate-017/>, <https://onco.cc/trials/checkmate-057/>, <https://onco.cc/trials/oak/>, <https://onco.cc/trials/keynote-010/>, <https://onco.cc/trials/revel/>, <https://onco.cc/trials/lume-lung-1/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/nintedanib/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/harmoni-2/>, <https://onco.cc/trials/harmoni-3/>, <https://onco.cc/trials/harmoni-a/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/dellphi-305/>, <https://onco.cc/trials/destiny-lung02/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/convert/>, <https://onco.cc/trials/turrisi-intergroup-0096/>, <https://onco.cc/trials/pci-overview-1999/>, <https://onco.cc/trials/takahashi-pci/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/astrum-005/>, <https://onco.cc/trials/imforte/>, <https://onco.cc/trials/crest-thoracic-rt/>, <https://onco.cc/trials/slotman-pci-es-sclc/>, <https://onco.cc/trials/takahashi-pci/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/trials/nct05060016/>, <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/dellphi-305/>, <https://onco.cc/trials/lurbinectedin-basket-sclc/>, <https://onco.cc/trials/atlantis/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/trials/sabr-comet/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/trials/time2/>, <https://onco.cc/trials/ample/>, <https://onco.cc/terms/lung-palliation-breathlessness-effusion-obstruction/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/pleural-effusion/>, <https://onco.cc/terms/palliative-treatment/>, <https://onco.cc/trials/dutch-bone-metastasis-study/>, <https://onco.cc/trials/jrosg-99-1/>, <https://onco.cc/trials/quartz/>, <https://onco.cc/trials/crown/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/terms/brain-metastases/> .